# Scilex Holding Co: financial statements, quarterly

SCLX · Nasdaq · CIK 1820190 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sclx.md) · [Financials](/companies/sclx/financials.md) · [Filings](/companies/sclx/filings.md) · [Insiders](/companies/sclx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sclx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [10.1](/filings/0000950170-25-006755.md) | [13.5 d](/filings/0000950170-25-047800.md) | [10.9](/filings/0000950170-25-071517.md) | [16.4](/filings/0000950170-25-108029.md) | [14.4](/filings/0001193125-25-283153.md) | [14.9 d](/filings/0001193125-26-151455.md) | [5.0](/filings/0001193125-26-232857.md) | [9.9](/filings/0001193125-26-352464.md) | [10.6](/filings/0001193125-25-283153.md) | [4.8 d](/filings/0001193125-26-151455.md) | [8.6](/filings/0001193125-26-232857.md) | [7.6](/filings/0001193125-26-352464.md) |
| Cost of revenue | $m | [3.4](/filings/0000950170-25-006755.md) | [4.5 d](/filings/0000950170-25-047800.md) | [3.8](/filings/0000950170-25-071517.md) | [4.4](/filings/0000950170-25-108029.md) | [3.8](/filings/0001193125-25-283153.md) | [4.7 d](/filings/0001193125-26-151455.md) | [1.4](/filings/0001193125-26-232857.md) | [3.3](/filings/0001193125-26-352464.md) | [3.3](/filings/0001193125-25-283153.md) | [2.6 d](/filings/0001193125-26-151455.md) | [4.4](/filings/0001193125-26-232857.md) | [3.7](/filings/0001193125-26-352464.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | [17.7](/filings/0001193125-26-232857.md) | [39.5](/filings/0001193125-26-352464.md) | not reported | not reported | [25.7](/filings/0001193125-26-232857.md) | [15.8](/filings/0001193125-26-352464.md) |
| Research and development | $m | [4.1](/filings/0000950170-25-006755.md) | [2.7 d](/filings/0000950170-25-047800.md) | [3.1](/filings/0000950170-25-071517.md) | [2.0](/filings/0000950170-25-108029.md) | [2.3](/filings/0001193125-25-283153.md) | [2.2 d](/filings/0001193125-26-151455.md) | [2.5](/filings/0001193125-26-232857.md) | [6.2](/filings/0001193125-26-352464.md) | [3.9](/filings/0001193125-25-283153.md) | [8.2 d](/filings/0001193125-26-151455.md) | [3.2](/filings/0001193125-26-232857.md) | [3.3](/filings/0001193125-26-352464.md) |
| Selling, general and administrative | $m | [40.4](/filings/0000950170-25-006755.md) | [23.5 d](/filings/0000950170-25-047800.md) | [29.3](/filings/0000950170-25-071517.md) | [24.6](/filings/0000950170-25-108029.md) | [29.7](/filings/0001193125-25-283153.md) | [35.4 d](/filings/0001193125-26-151455.md) | [28.1](/filings/0001193125-26-232857.md) | [19.8](/filings/0001193125-26-352464.md) | [189](/filings/0001193125-25-283153.md) | [30.2 d](/filings/0001193125-26-151455.md) | [31.0](/filings/0001193125-26-232857.md) | [28.0](/filings/0001193125-26-352464.md) |
| Operating income | $m | [(38.8)](/filings/0000950170-25-006755.md) | [(18.3) d](/filings/0000950170-25-047800.md) | [(19.5)](/filings/0000950170-25-071517.md) | [(15.6)](/filings/0000950170-25-108029.md) | [(19.9)](/filings/0001193125-25-283153.md) | [(28.4) d](/filings/0001193125-26-151455.md) | [(27.9)](/filings/0001193125-26-232857.md) | [(20.5)](/filings/0001193125-26-352464.md) | [(187)](/filings/0001193125-25-283153.md) | [(111) d](/filings/0001193125-26-151455.md) | [(32.2)](/filings/0001193125-26-232857.md) | [(29.4)](/filings/0001193125-26-352464.md) |
| Interest expense | $m | [0.5](/filings/0000950170-23-063810.md) | [0.6 d](/filings/0000950170-24-029473.md) | [0.5](/filings/0000950170-24-058630.md) | [0.6](/filings/0000950170-24-096199.md) | [0.6](/filings/0001193125-25-283153.md) | [0.3 d](/filings/0001193125-26-151455.md) | [2.5](/filings/0001193125-26-232857.md) | [2.7](/filings/0001193125-26-352464.md) | [2.8](/filings/0001193125-25-283153.md) | [3.5 d](/filings/0001193125-26-151455.md) | [3.8](/filings/0001193125-26-232857.md) | [6.1](/filings/0001193125-26-352464.md) |
| Income tax | $m | [0.0](/filings/0000950170-25-006755.md) | [0.0 d](/filings/0000950170-25-047800.md) | [0.0](/filings/0000950170-24-058630.md) | [0.0](/filings/0000950170-25-108029.md) | [0.0](/filings/0001193125-25-283153.md) | [(0.0) d](/filings/0001193125-26-151455.md) | not reported | [0.0](/filings/0001193125-26-352464.md) | [0.0](/filings/0001193125-25-283153.md) | [0.0 d](/filings/0001193125-26-151455.md) | not reported | [0.0](/filings/0001193125-26-352464.md) |
| Net income | $m | [(35.5)](/filings/0000950170-25-006755.md) | [(21.4) d](/filings/0000950170-25-047800.md) | [(24.4)](/filings/0001193125-25-283153.md) | [(37.6)](/filings/0001193125-25-283153.md) | [(4.4)](/filings/0001193125-25-283153.md) | [(6.5) d](/filings/0001193125-26-151455.md) | [(26.1)](/filings/0001193125-26-352464.md) | [(44.0)](/filings/0001193125-26-352464.md) | [(258)](/filings/0001193125-25-283153.md) | [(46.1) d](/filings/0001193125-26-151455.md) | [(45.7)](/filings/0001193125-26-352464.md) | [(115)](/filings/0001193125-26-352464.md) |
| Diluted EPS | $ per share | [(0.63)](/filings/0000950170-25-006755.md) | not reported | [(8.33)](/filings/0000950170-25-071517.md) | [(7.67)](/filings/0000950170-25-108029.md) | [(0.58)](/filings/0001193125-25-283153.md) | not reported | [(2.26)](/filings/0001193125-26-232857.md) | [(7.42)](/filings/0001193125-26-352464.md) | [(22.17)](/filings/0001193125-25-283153.md) | not reported | [(6.28)](/filings/0001193125-26-232857.md) | [(16.65)](/filings/0001193125-26-352464.md) |
| Basic EPS | $ per share | [(0.63)](/filings/0000950170-25-006755.md) | not reported | [(8.33)](/filings/0000950170-25-071517.md) | [(7.67)](/filings/0000950170-25-108029.md) | [(0.58)](/filings/0001193125-25-283153.md) | not reported | [(2.26)](/filings/0001193125-26-232857.md) | [(7.42)](/filings/0001193125-26-352464.md) | [(22.17)](/filings/0001193125-25-283153.md) | not reported | [(6.28)](/filings/0001193125-26-232857.md) | [(16.65)](/filings/0001193125-26-352464.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [2.0](/filings/0000950170-23-063810.md) | [3.9](/filings/0000950170-25-047800.md) | [1.8](/filings/0000950170-24-058630.md) | [6.9](/filings/0000950170-24-096199.md) | [0.1](/filings/0000950170-25-006755.md) | [3.3](/filings/0001193125-26-151455.md) | [5.8](/filings/0000950170-25-071517.md) | [4.1](/filings/0000950170-25-108029.md) | [0.9](/filings/0001193125-25-283153.md) | [5.0](/filings/0001193125-26-352464.md) | [3.4](/filings/0001193125-26-232857.md) | [0.6](/filings/0001193125-26-352464.md) |
| Current assets | $m | [25.5](/filings/0000950170-23-063810.md) | [46.8](/filings/0000950170-25-047800.md) | [37.7](/filings/0000950170-24-058630.md) | [50.4](/filings/0000950170-24-096199.md) | [39.9](/filings/0000950170-25-006755.md) | [41.5](/filings/0001193125-26-151455.md) | [28.7](/filings/0000950170-25-071517.md) | [33.7](/filings/0000950170-25-108029.md) | [16.5](/filings/0001193125-25-283153.md) | [38.4](/filings/0001193125-26-352464.md) | [42.0](/filings/0001193125-26-232857.md) | [36.2](/filings/0001193125-26-352464.md) |
| Total assets | $m | [80.5](/filings/0000950170-23-063810.md) | [101](/filings/0000950170-25-047800.md) | [91.2](/filings/0000950170-24-058630.md) | [105](/filings/0000950170-24-096199.md) | [100](/filings/0000950170-25-006755.md) | [93.0](/filings/0001193125-26-151455.md) | [79.0](/filings/0000950170-25-071517.md) | [83.8](/filings/0000950170-25-108029.md) | [276](/filings/0001193125-25-283153.md) | [365](/filings/0001193125-26-352464.md) | [294](/filings/0001193125-26-232857.md) | [254](/filings/0001193125-26-352464.md) |
| Current liabilities | $m | [229](/filings/0000950170-23-063810.md) | [250](/filings/0000950170-25-047800.md) | [253](/filings/0000950170-24-058630.md) | [255](/filings/0000950170-24-096199.md) | [282](/filings/0000950170-25-006755.md) | [260](/filings/0001193125-26-151455.md) | [276](/filings/0000950170-25-071517.md) | [306](/filings/0000950170-25-108029.md) | [359](/filings/0001193125-25-283153.md) | [484](/filings/0001193125-26-352464.md) | [502](/filings/0001193125-26-232857.md) | [512](/filings/0001193125-26-352464.md) |
| Total liabilities | $m | [243](/filings/0000950170-23-063810.md) | [274](/filings/0000950170-25-047800.md) | [281](/filings/0000950170-24-058630.md) | [319](/filings/0000950170-24-096199.md) | [312](/filings/0000950170-25-006755.md) | [286](/filings/0001193125-26-151455.md) | [290](/filings/0000950170-25-071517.md) | [333](/filings/0000950170-25-108029.md) | [456](/filings/0001193125-25-283153.md) | [577](/filings/0001193125-26-352464.md) | [548](/filings/0001193125-26-232857.md) | [564](/filings/0001193125-26-352464.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [115](/filings/0000950170-23-063810.md) | [108](/filings/0000950170-25-047800.md) | [92.9](/filings/0000950170-24-058630.md) | [75.4](/filings/0000950170-24-096199.md) | [84.6](/filings/0000950170-25-006755.md) | [34.9](/filings/0001193125-26-151455.md) | [39.4](/filings/0000950170-25-071517.md) | [39.9](/filings/0000950170-25-108029.md) | [45.7](/filings/0001193125-25-283153.md) | [83.3](/filings/0001193125-26-352464.md) | [80.8](/filings/0001193125-26-232857.md) | [80.8](/filings/0001193125-26-352464.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(163)](/filings/0000950170-23-063810.md) | [(173)](/filings/0000950170-25-047800.md) | [(190)](/filings/0000950170-24-058630.md) | [(215)](/filings/0000950170-24-096199.md) | [(211)](/filings/0000950170-25-006755.md) | [(193)](/filings/0001193125-26-151455.md) | [(211)](/filings/0000950170-25-071517.md) | [(249)](/filings/0000950170-25-108029.md) | [(177)](/filings/0001193125-25-283153.md) | [(208)](/filings/0001193125-26-352464.md) | [(249)](/filings/0001193125-26-232857.md) | [(308)](/filings/0001193125-26-352464.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: us-gaap:DebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [5.9 d](/filings/0000950170-25-006755.md) | [(5.4) d](/filings/0000950170-25-047800.md) | [9.4](/filings/0000950170-25-071517.md) | [2.3 d](/filings/0000950170-25-108029.md) | [5.1 d](/filings/0001193125-25-283153.md) | [2.5 d](/filings/0001193125-26-151455.md) | [6.0](/filings/0001193125-26-232857.md) | [7.1 d](/filings/0001193125-26-352464.md) | [8.2 d](/filings/0001193125-25-283153.md) | [(17.5) d](/filings/0001193125-26-151455.md) | [(1.1)](/filings/0001193125-26-232857.md) | [(6.7) d](/filings/0001193125-26-352464.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-25-006755.md) | [0.0 d](/filings/0000950170-25-047800.md) | not reported | not reported | [0.0 d](/filings/0000950170-25-006755.md) | [0.0 d](/filings/0001193125-26-151455.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $m | not reported | [0.0 d](/filings/0000950170-24-029473.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [133](/filings/0000950170-23-063810.md) | [0.1](/filings/0000950170-24-058630.md) | [0.1](/filings/0000950170-24-096199.md) | [0.1](/filings/0000950170-25-006755.md) | [0.0](/filings/0000950170-25-071517.md) | [0.0](/filings/0000950170-25-108029.md) | [0.0](/filings/0001193125-25-283153.md) | [11.6](/filings/0001193125-26-232857.md) | [11.6](/filings/0001193125-26-352464.md) | [0.0](/filings/0001193125-25-283153.md) | [6.9](/filings/0001193125-26-232857.md) | [6.9](/filings/0001193125-26-352464.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 8,493,000 at 2026-08-10, from the cover of the [10-Q filed 2026-08-14](/filings/0001193125-26-352464.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.